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Abstract
Purpose To compare the performance of eight metabolic
indices for the early assessment of tumour response in
patients with metastatic colorectal cancer (mCRC) treated
with chemotherapy.
Methods Forty patients with advanced mCRC underwent
two FDG PET/CT scans, at baseline and on day 14 after
chemotherapy initiation. For each lesion, eight metabolic
indices were calculated: four standardized uptake values
(SUV) without correction for the partial volume effect
(PVE), two SUV with correction for PVE, a metabolic
volume (MV) and a total lesion glycolysis (TLG). The
relative change in each index between the two scans
was calculated for each lesion. Lesions were also clas-
sified as responding and nonresponding lesions using
the Response Evaluation Criteria In Solid Tumours
(RECIST) 1.0 measured by contrast-enhanced CT at
baseline and 6–8 weeks after starting therapy. Bland-
Altman analyses were performed to compare the various
indices. Based on the RECIST classification, ROC
analyses were used to determine how accurately the
indices predicted lesion response to therapy later seen
with RECIST.
Results RECIST showed 27 responding and 74 nonres-
ponding lesions. Bland-Altman analyses showed that the
four SUV indices uncorrected for PVE could not be used
interchangeably, nor could the two SUV corrected for
PVE. The areas under the ROC curves (AUC) were not
significantly different between the SUV indices not cor-
rected for PVE. The mean SUV change in a lesion better
predicted lesion response without than with PVE correc-
tion. The AUC was significantly higher for SUV uncor-
rected for PVE than for the MV, but change in MV
provided some information regarding the lesion response
to therapy (AUC >0.5).
Conclusion In these mCRC patients, all SUV uncorrected
for PVE accurately predicted the tumour response on day
14 after starting therapy as assessed 4 to 6 weeks later
(i.e. 6 to 8 weeks after therapy initiation) using the
RECIST criteria. Neither correcting SUV for PVE nor
measuring TLG improved the assessment of tumour re-
sponse compared to SUV uncorrected for PVE. The
change in MV was the least accurate index for predicting
tumour response.
Keywords Partial volume effect . Treatment response .
SUV . Classification performances . FDG PET . Colorectal
cancer
Introduction
PET/CT is a promising tool for detecting molecular sig-
nals associated with tumour response soon after therapy
initiation (e.g. [1–4]). To help standardize procedures and
achieve comparable quantitative measurements among
J.-A. Maisonobe :H. Necib : I. Buvat (*)
IMNC UMR 8165 CNRS – Paris 7 and Paris 11 Universities,
Building 440, Orsay Campus,




C. A. Garcia :B. Vanderlinden : P. Flamen
Department of Nuclear Medicine, Institut Jules Bordet,
Université Libre de Bruxelles,
Brussels, Belgium
A. Hendlisz
Department of Gastroenterology, Institut Jules Bordet,
Université Libre de Bruxelles,
Brussels, Belgium
Eur J Nucl Med Mol Imaging (2013) 40:166–174
DOI 10.1007/s00259-012-2274-x
institutions using 18F-FDG PET/CT, guidelines and rec-
ommendations are being been proposed [5–7]. Yet, there
is still a lack of consensus as to which index to use to
characterize tumour metabolism. The European Organiza-
tion for Research and Treatment of Cancer recommends
the use of the metabolic glucose rate derived from a
kinetic analysis and based on the measurement of the
time-course of radioactivity in tissue and arterial blood,
or the mean or maximum standardized uptake value
(SUV) normalized to body surface area [5]. PERCIST
1.0 [6] advocates the use of an SUV normalized to lean
body mass (SUL) computed in a small sphere (about
1 cm3) including the tumour voxel of maximum intensity
so that the mean value in the sphere is maximized
(SULpeak). PERCIST 1.0 also suggests reporting the max-
imum SUL in the tumour, the mean SUL in volumes
containing voxels with SUL greater than 50 % or 70 %
of SULpeak and/or the total lesion glycolysis (TLG [8]).
Although the maximum SUV in the tumour (SUVmax)
is by far the most reported index [6, 9], the most rele-
vant index in the context of patient monitoring remains
to be identified. It has been shown that the accuracy,
robustness, classification performance and test–retest var-
iability of semiquantitative indices greatly depend on the
definition of the index [10–13]. Cheebsumon et al. [14]
recently showed that absolute quantitation using metabol-
ic glucose rate might yield an interpretation different
from that based on SUV in the context of patient mon-
itoring. The role of the TLG index, which includes
information regarding the metabolically active volume
(MV) and the uptake in this volume, also needs to be
clarified [15, 16].
The partial volume effect (PVE) is one of the main
sources of error in the quantitative characterization of
tumour metabolism in FDG PET/CT [16]. The way it is
dealt with might have an impact on early tumour response
assessment [17, 18]. Indeed, due to PVE, SUV often
reflects both the metabolic activity and the MV [19],
especially in small lesions. The severity of PVE can be
reduced by modelling the imaging system point spread
function during the reconstruction process [20, 21]. PVE
can also be compensated for by postprocessing the recon-
structed images [22] or the values derived from those
images [23, 24]. Recent reviews regarding the various
approaches that might be used to correct for PVE are
available [17, 19].
The aim of this study was to clarify the impact of PVE and
PVE correction on the early assessment of tumour response in
patients with metastatic colorectal cancer (mCRC) treated
with polychemotherapy. We compared the performance of
eight indices (four SUV indices without PVE correction, two
SUVs compensated for PVE, a MV index and a TLG index)
derived from a PET/CT scan performed 2 weeks after
treatment initiation to predict the tumour response determined
using the RECIST 1.0 criteria 6 to 8 weeks after treatment.
Materials and methods
Patients
Forty patients with advanced mCRC treated at the Institute
Jules Bordet, Brussels, Belgium, were enrolled in the study.
The patients’ characteristics are shown in Table 1. The patients
were recruited as part of a prospective clinical trial in a larger
cohort of patients, the aim of the clinical trial being to assess the
clinical role of early FDG PET/CT scanning in chemotherapy-
treated mCRC [13, 25]. The study was approved by the ethics
committee of the Institute Jules Bordet and registered at clin-
icaltrials.gov (number NCT00741481). The patients’ treatment
regimens are listed in Table 1. No targeted drugs (anti-VEGF,
anti-EGFR) were used.
Table 1 Patient characteristics
Characteristic Value
Total number of patients 40















Male 23 (58 %)
Female 17 (42 %)
Line of treatment (n)
First 29 (72 %)
Second 11 (28 %)
Treatment regimen (n)
FOLFOX 20 (50 %)
FOLFIRI 13 (33 %)
FOLFOX + bevacizumab 1 (3 %)
FOLFIRI + bevacizumab 4 (10 %)
FOLFIRI + panitumumab 1 (3 %)
Capecitabine 1 (3 %)
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Computed tomography
Each patient underwent a helical diagnostic CT scan with or
without intravenous injection of contrast agent (depending on
the lesion) 9 days on average (range 0–26 days) before the first
FDG PET/CTscan, and after 6 to 8 weeks on therapy or sooner
in patients with clinical suspicion of progression (three
patients). Axial slice thickness was 3 or 5 mm depending on
the CT scanner. The target lesions (no more than five per
patient) were identified by a senior radiologist in a joint reading
session with a nuclear medicine physician. Each lesion was
analysed individually.
CT data were interpreted according to the RECIST 1.0
criteria [26] with the following restriction: only lesions clearly
identified on both the baseline PET and diagnostic CT scans
and with a diameter of at least 15 mm on the baseline diag-
nostic CT scan were analysed. Based on RECIST 1.0, lesions
were classified as complete response to the treatment (CR),
partial response (PR), stable disease (SD) and progressive
disease (PD). Confirmation of SD status was obtained by an
additional CT scan after a further 6 to 8 weeks.
FDG PET/CT
Each patient underwent a baseline FDG PET/CT scan just
before the start of chemotherapy and a second scan on day
14 after chemotherapy initiation. Patient preparation, imaging
and reconstruction protocols were identical for serial scans. All
FDG PET/CT images were acquired using a GE Discovery LS
system, 60 min after injection of 4 MBq/kg. PET images were
reconstructed with the built-in GE Healthcare Advance soft-
ware, using the ordered subset expectation maximization algo-
rithm [27] with two iterations and 28 subsets, and postfiltered
with a 5.45-mm full-width at half-maximum (FWHM) gauss-
ian function. The images were corrected for attenuation using
the CT data and for scatter using a convolution-subtraction
method [28]. CTwas performed with a four-slice helical scan-
ner (LightSpeed; GE Medical Systems). The tension was
120 kV and the current was determined by the Auto-mA GE
algorithm and ranged from 30 mA to 200 mA. The other CT
acquisition parameters were 0.5 s per CT rotation, with a pitch
of 1.5 and a table speed of 15 mm per rotation. The matrix of
CT images was 512 × 512 (0.98 × 0.98 mm pixel size) with a
5-mm slice thickness, and the PET matrix was 128 × 128
pixels of 3.91 × 3.91 mm with a slice thickness of 4.25 mm.
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Characterization of tumour metabolism
Eight indices were used to quantify the tumour PET signal.
All indices were calculated inside a large and manually
defined volume of interest (VOI) centred on the lesion and
including at least 50 % background activity. When required,
the volume was adjusted so that only one hot region was
contained in each VOI. These delineations were all per-
formed by the same investigator using a research version
of OWS software (Dosisoft, version 1.0.0.2.8).
Metabolically active volume The lesion MV was obtained
using the delineation method proposed by Nestle et al. [29].
The threshold value, Tbgd, used for the delineation process
was defined by:
Tbgd ¼ a  SUV70 þ SUVbgd ð2Þ
To ensure connectivity between the voxels that define the
MV, the largest region of connected voxels obtained after
the application of this threshold was selected as the MV. The
volume obtained using this algorithm depends on the mean
uptake SUV70 in a region containing voxels with a value
greater than 70 % of the maximum value in the VOI and on
the surrounding background activity, SUVbgd. SUVbgd was
defined as the mean uptake in a 3-D shell region of 8 mm
thickness placed at 16 mm from a region including all the
contiguous voxels with uptake greater than 40 % of the
maximum. To avoid the inclusion of irrelevant voxels, the
boundaries of the background region were kept inside the
VOI previously defined.
The α parameter in Eq. 2 was optimized using three
acquisitions in a Jaszczak phantom composed of six spheres
(volumes of 0.5, 1, 2, 4, 8 and 16 mL). The three acquis-
itions were performed using the same PET/CT scanner and
acquisition protocol as for the patients. The only parameter
varying between the three scans was the activity ratio be-
tween the sphere and the background regions. These ratios
were 2.96:1, 5.88:1 and 10:1. A value of α00.3 was
obtained by minimizing the average absolute error between
the true sphere volumes and the volumes measured using
Tbgd where the average error was calculated over all spheres
and contrasts. We checked that this α value was robust with
respect to the size of the spheres included in the optimiza-
tion (results not shown).
SUV Six SUV indices were calculated, including four indi-
ces without PVE correction and two with PVE correction.
SUVmax was calculated as the maximum SUV in the
tumour volume MV defined above.
SUVpeak was computed as the average in a region of
3 × 3 × 3 voxels (1.75 mL) centred on the voxel
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corresponding to SUVmax.. Note that this is not identi-
cal to the SULpeak index recommended in PERCIST.
SUV70 was equal to the mean uptake in a region contain-
ing voxels with a value greater than 70 % of the maxi-
mum value in the large tumour VOI.
SUVmean was defined as the average SUV in the MV
defined above.
SUVrc was equal to SUVmean corrected for PVE using a
recovery coefficient (RC) [23, 24]. The RC was calculated
by convolving a binary mask corresponding to the MV
with a 3-D gaussian function of FWHM equal to 7 mm.
This 7-mm value was estimated by minimizing the mean
square error in MV of the 18 spheres from the Jaszczak
phantom images (six spheres × three contrast values). Spill-
in was taken into account using SUVbgd defined above.
SUVdecon was obtained by performing a 3-D PET image
deconvolution based on the Van Cittert iterative algorithm
[22], using 12 iterations and a convergence rate set to 1. A
mean SUV was then calculated in a 3-D region obtained
using the region used to calculate SUV70 in Eq. 2.
Total lesion glycolysis The TLG of each lesion was calculated
as the product of MV with SUVmean [8].
For each index and each patient, the percent change
between the two scans was calculated for each lesion.
For instance, with SUVmean, the percent change was
given by:
Δ SUVmean %ð Þ ¼ 100 SUVmean D14ð Þ  SUVmean Baselineð ÞSUVmean Baselineð Þ
ð3Þ
where D14 denotes the measurements performed on the
PET/CT scan acquired after 14 days of treatment.
Data analysis
The mean, standard deviation and range values over all lesions
were calculated for each of the eight indices, at baseline and after
2 weeks of treatment. The agreement between indices in the
baseline scans was evaluated using Bland-Altman plots [30].
The mean percent changes of the metabolic indices between
baseline and day 14 were calculated for two groups of lesions:
1. The responding tumour group was defined as all lesions
classified as PR or CR in the sense of the RECIST 1.0
criteria.
2. The nonresponding tumour group was defined as all
lesions classified as PD or SD by RECIST 1.0.
Given that the statistical distributions of our indices in these
two lesion groups departed significantly from normal
distributions (Smirnov-Kolmogorov test), the significance of
the differences between the medians of the percent change for
the responding and nonresponding tumours was tested using a
Wilcoxon signed ranks test with a significance level of 0.05.
To compare the performance of the eight indices in predicting
the response to chemotherapy as later determined by RECIST, a
nonparametric receiver operating characteristic (ROC) analysis
was performed [31] using the responding and nonresponding
tumour groups defined above. ROC curves were characterized
by the area under the curve (AUC) and the significance of the
difference between AUCs was tested using a nonparametric
Friedman two-way analysis of variance by ranks [32].
Finally, the variability in each index was characterized
using the coefficient of variation (CV, Eq. 4) of the absolute
change between the two scans (Eq. 5).










with Δindexlesion and Δindex defined as:





lesion¼1 indexlesion D14ð Þ  indexlesion Baselineð Þj j
ð6Þ
CV was calculated only for the 55 tumours classified as
SD according to the RECIST 1.0 criteria. Indeed, for these
lesions, the index change between the two scans would be
expected to be negligible, and CV therefore represents
mostly the variability of the index under similar conditions.
Results
Tumours
In the 40 patients, the mean number of lesions per patient
was three (range one to eight). A total of 101 lesions
selected according to the procedure outlined in the section
Computed tomography were analysed (3 were primary
lesions, 70 were located in the liver, 12 in the lungs, 9 in
the peritoneum, and 7 at other various locations; Table 1). In
these lesions, RECIST 1.0 classification yielded 27 PR, 55
SD and 19 PD lesions, and no CR lesions.
Tumour metabolic volumes
The tumour MVs of the 101 lesions at baseline ranged from
1.0 to 382 mL (mean 34.4 ± 66.4 mL, median 8.5 mL).
Figure 1 shows the distribution of tumour volumes at baseline
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for all tumours together, and also for the responding and
nonresponding tumours separately. A chi-squared test showed
that the distribution between the two volume groups at base-
line (volume less than and more than 5 mL) was not signifi-
cantly different between the responding and nonresponding
tumours.
Metabolic indices
The calculated values of the metabolic indices are given in
Table 2. All indices showed a significant decrease after 2weeks
of chemotherapy (p<0.05, two-sided Wilcoxon signed ranks
test). The median percent changes in the indices between
responding and nonresponding tumours were significantly
different for all indices except MV (Mann-Whitney test).
Bland-Altman plots
Figure 2 shows the Bland-Altman plots comparing the meta-
bolic indices uncorrected for PVE (Fig. 2a–f) and comparing
the two indices corrected for PVE (Fig. 2g). The strong linear
relationship seen in most plots (except Fig. 2f) suggests that
the two compared values were highly correlated. For instance,
SUVrc was, on average, 70 % of SUVdecon (Fig. 2h).
ROC curve analysis
Figure 3 shows the ROC curves for detecting lesion response
to therapy for the eight indices. The AUCs (means ± SD)
associated with the ROC curves were 0.81±0.04 for SUVmean,
0.79±0.05 for SUVpeak, 0.77±0.05 for SUVmax, 0.77±0.06
for SUVrc, 0.75±0.05 for SUV70, 0.74±0.06 for TLG, 0.69±
0.06 for SUVdecon, and 0.58±0.07 for MV.
A nonparametric Friedman two-way analysis of variance
by ranks showed that the eight AUCs were not all identical.
Comparisons of all pairs of AUCs using a multiple compar-
ison procedure showed that only SUVmean, SUV70 and
SUVrc yielded an AUC significantly greater than that of
MV (p<0.05), while SUVmax, SUVdecon, SUVpeak and
TLG did not. SUVdecon showed poor classification perfor-
mance, with an AUC substantially smaller than all AUCs
associated with the other SUV indices. No other pairs of
indices had significantly different AUCs.
Coefficients of variation
The CVs for the change between the two scans for the 55
SD tumours were 0.72 for SUVmean, 0.82 for SUVpeak, 0.76
for SUVmax and SUVrc, 0.75 for SUV70, 1.00 for SUVdecon,
1.90 for TLG and 1.70 for MV.
Discussion
The aim of this study was to clarify the impact of the index
used for characterizing the metabolic activity of a lesion on
FDG PET images when assessing the change in a lesion
Fig. 1 Percentages of tumours with a volume less than 5 mL and
greater than 5 mL considering all tumours (left), only responding
tumours (centre), and only nonresponding tumours (right)
Table 2 Calculated values of the eight indices for all lesions at baseline and on day 14 of treatment presented as means ± SD (min; max). The
median percent changes after 2 weeks of treatment for responding and nonresponding tumours are also shown
Index Baseline Day 14 Change (%)
Responding tumours Nonresponding tumours
SUVmean (g/mL) 6.1 ± 2.2 (1.7; 12.4) 5.1 ± 1.9 (1.2; 10.4)* −30.5 ± 15.2 (−72.4; −8.4) −6.7 ± 29.9* (−56.5; 171.1)
SUVpeak (g/mL) 7.4 ± 3.4 (1.4; 21.3) 6.0 ± 2.9 (1.1; 18.0)* −33.5 ± 17.0 (−74.0; −3.4) −8.8 ± 37.1* (−8.8; 250.4)
SUV70 (g/mL) 8.3 ± 3.4 (2.1; 18.5) 6.9 ± 3.1 (1.3; 17.1)* −31.0 ± 18.3 (−79.4; −1.5) −7.3 ± 41.4* (−66.7; 276.3)
SUVmax (g/mL) 10.5 ± 4.3 (2.5; 22.3) 8.7 ± 3.9 (1.5; 21.1)* −32.3 ± 18.3 (−78.1; 3.5) −6.9 ± 37.3* (−66.7; 226.7)
SUVrc (g/mL) 7.9 ± 2.7 (2.5; 14.6) 6.7 ± 2.5 (1.7; 12.9)* −29.3 ± 18.2 (−76.6; −0.2) −6.3 ± 30.0* (−56.3; 151.2)
TLG (g) 252.4 ± 559.3 (3.6; 3,644.9) 161.1 ± 293.6 (2.2; 1,574.3)* −37.2 ± 40.7 (−81.2; 133.1) 3.3 ± 109.9* (−76.6; 834.1)
SUVdecon (g/mL) 11.7 ± 4.7 (3.1; 27.2) 9.8 ± 4.5 (1.8; 21.9)* −28.0 ± 22.4 (−83.8; 6.7) −6.6 ± 45.0* (−73.6; 261.6)
MV (mL) 34.4 ± 66.4 (1.0; 381.5) 27.4 ± 45.7 (1.0; 262.4)* −4.9 ± 61.4 (−77.1; 218.2) 6.0 ± 59.2 (−74.9; 254.9)
*(column 3)p<0.05, day 14 vs. baseline; *(column 5)p<0.05, responding vs. nonresponding tumours.
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between a baseline scan and an early follow-up PET scan,
performed 2 weeks after starting chemotherapy. In particu-
lar, the relevance of indices corrected for PVE in that con-
text was investigated.
Index values
All SUV-based indices are assumed to characterize the
metabolic activity of a lesion. Yet the Bland-Altman plots
(Fig. 2) demonstrate that one SUV index cannot be replaced
by another. By definition, SUVmax is greater than SUVmean
and SUVpeak, and Fig. 2a and c shows that the larger the
SUV, the greater the difference between the two indices.
Also, SUVpeak exceeded SUVmean on average, although it
could be smaller for small tumours, in which SUVmax some-
times corresponds to a voxel near the edge of the lesion and
surrounded by low activity values “outside” the tumour. By
definition, these low activity values are included when cal-
culating SUVpeak but not when calculating SUVmean, there-
for making SUVpeak lower than SUVmean. Figure 2 shows
that for all SUV indices not corrected for PVE, the value
depends more on the calculation approach (SUVpeak, SUV-
max, SUV70 or SUVmean) for lesions with large SUV than for
lesions with small SUV. The strong linear relationships seen
on most Bland-Altman plots suggest that on average, one
index can be roughly deduced from another using scaling
factors, as illustrated in Fig. 2h. For instance, on average,
SUVmax was 46 % greater than SUVpeak, 71 % greater than
SUVmean, and 24 % greater than SUV70.
Regarding the variability in the indices, the coefficients
of variation suggest that all SUV indices not corrected for
PVE had similar variability, which was between 2.1 and 2.4
times less than that of MV. The variability in TLG was the
largest among all indices.
PVE corrections
It is well known that PVE results in the largest underestima-
tion of uptake in small tumours [19], especially in those whose
dimensions are less than three times the spatial resolution in
the reconstructed images. The spatial resolution in our PET
Fig. 2 a–g Bland-Altman plots comparing indices for the 101 lesions
before the first cycle of chemotherapy. The mean difference between
each pair of indices and the mean ± 2SD are shown as solid and dotted
lines, respectively, with the corresponding values in parentheses. h Plot
of the ratio between SUVrc and SUVdecon as a function of the mean,
demonstrating that the two values are highly correlated
Fig. 3 ROC curves for the SUVmean, SUVpeak, SUVmax, SUV70,
SUVrc, SUVdecon and MV indices calculated from PET/CT scans
performed on day 14 of therapy for the identification of responding
(n027) and nonresponding (n074) lesions as defined by the RECIST
1.0 classification 6 to 8 weeks after treatment
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images was about 7 mm FWHM, and hence tumours less than
about 5 mLwere strongly affected by PVE. This corresponded
to 28 % of the 101 lesions. We could not restrict our analysis
to these lesions because the number of tumours was then too
low to demonstrate any significant difference between the
responding/nonresponding tumour groups by the different
indices. We thus considered all lesions in our analysis, check-
ing that the proportions of small (≤5 mL) and large (>5 mL)
tumours were not significantly different in the responding and
nonresponding tumour groups (Fig. 1).
Two postreconstruction PVE corrections were tested. In the
one using the Van Cittert iterative algorithm [22], the number
of iterations should be carefully set to avoid a high increase in
noise in the resulting images [33, 34]. We checked that our
results remained unchanged in terms of statistical difference
between differences in AUC when using 4 iterations instead of
12 in the Van Cittert algorithm. Another parameter of this PVE
correction is the threshold (expressed as the percent of the
maximum value in the tumour) used to calculate the PVE-
corrected uptake in the deconvolved image. The 80 % thresh-
old proposed by Teo et al. [22] was too high for our data and
did not yield a VOI with spatially connex voxels. We used a
70 % threshold instead, i.e. exactly the same region as the one
used to calculate SUV70 involved in theMV calculation so that
SUV70 and SUVdecon only differed in terms of PVE correction.
We also implemented the Lucy-Richardson [35] deconvolution
and did not find any significant difference compared to the Van
Cittert deconvolution, in agreement with Hoetjes et al. [17].
The other PVE correction we tested used RC and required an
estimate of the spatial resolution in the reconstructed images.
Our conclusions remained unchanged when assuming that the
spatial resolution was 6 mm FWHM or 8 mm FWHM instead
of the 7 mm value used in the results presented.
Because of PVE, the measured FDG uptake is strongly
correlated with the tumour volume [19]. To assess the ef-
fectiveness of our two PVE corrections, we calculated the
Pearson correlation coefficient between MV and each SUV
index, at baseline and after one cycle of chemotherapy. This
correlation coefficient was found to be much lower for the
two PVE-corrected SUV indices (0.14 for SUVrc and 0.09
for SUVdecon) than for the uncorrected SUV (0.29 for
SUVmean, 0.40 for SUVpeak, 0.36 for SUVmax and 0.23 for
SUV70), suggesting that the PVE corrections were effective.
Unlike SUVrc, SUVdecon was not significantly linearly cor-
related with MV (p00.21). Looking closely at the differ-
ences between SUVrc and SUVdecon, SUVdecon was on
average larger than SUVrc (Table 2; Fig. 2g, h), which is
also consistent with the fact that SUVdecon appeared to be
more effective than SUVrc. The activity recovery produced
by PVE correction in the tumour volume used to calculate
SUV70, given by SUVdecon/SUV70, was 1.43 (SD 0.22)
when averaging over all lesions. The mean activity recovery
produced by PV correction using the RC, given by SUVrc/
SUVmean, was 1.33 (SD 0.14). These two close values
confirm that the two PVE corrections were effective, and
that the differences in results were mostly due to the regions
in which the tumour activity was measured.
Percent change in the indices between the two scans
The only metabolic index for which the mean percent change
between the two scans was not significantly different between
responding and nonresponding tumours was MV (Table 2).
This is in agreement with the findings of Cheebsumon et al.
[11] who found larger test–retest variability for MV than for
SUV. This is partly because tumour delineation in PET is
extremely challenging due to the low spatial resolution of
PET compared to CT and to the relatively high noise level in
PET images [36]. In addition, the chemotherapy-induced
shrinkage of tumour volume is a slow process, with a decrease
in volume after 2 weeks (one cycle) in responding lesions that
is not yet significant. This explains at least partially why PVE
correction in this setting does not increase the value of serial
FDG PET scans in predicting response.
The ROC curves (Fig. 3) show that all SUV indices had
similar performance in distinguishing between responding
and nonresponding lesions as later classified by the RECIST
1.0 criteria, except SUVdecon which yielded an ROC closer
to the diagonal line of no discrimination than the other SUV
indices. The ROC curves also show that the change in MV
provides some information to distinguish between respond-
ing and nonresponding lesions (AUC >0.5, p<10−5). Even
though it is far less informative than the SUV-based indices,
removing this piece of information embedded in indices not
corrected for PVE might be detrimental, as observed when
comparing the ROC curves associated with SUVrc and
SUVdecon with those associated with SUV not corrected
for PVE (Fig. 3). In particular, SUVdecon corresponding to
the seemingly most effective PVE correction had a poorer
classification performance than the SUV indices not cor-
rected for PVE, as shown by the location of the ROC curve.
This poor classification performance might also be
explained by the high variability in SUVdecon, compared to
the other indices not corrected for PVE (see CV). Yet the
TLG index had a much greater CV than SUVdecon and still a
substantially higher AUC (0.74). This suggests that the poor
performance of SUVdecon cannot be fully explained by its
high variability. Comparing SUVrc and SUVmean alone (ig-
noring all other indices), which are two indices calculated
from exactly the same voxels but with and without PVE
correction, it appears that the PVE correction actually sig-
nificantly reduced the AUC describing the classification
performance (p00.02). The same was true when comparing
only the AUC of SUVdecon and that of SUV70 (p00.03). By
removing the volume information implicitly contained in
SUVmean or SUV70 because of PVE, SUVrc and SUVdecon
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conveyed less information regarding the tumour response
than when the volume information was implicitly included.
If the early change in MV is relevant for assessing tumour
response, so should be the change in TLG, as MV is included
in TLG. We indeed observed that TLG had classification
performance not significantly different from that of the SUV
indices not corrected for PVE. TLG also had better classifica-
tion performance than SUVdecon (which does not include any
volume information) despite a greater CV. This result confirms
that what made SUVdecon poor in this classification task is the
lack of embedded volume information rather than the high
variability. We also investigated whether a TLG index calcu-
lated as the product of MV and an SUV corrected for PVE
could better distinguish responding from nonresponding
tumours than when TLG is based on an SUV not corrected
for PVE. With TLG defined as the product of SUVdecon and
MV, the AUC was 0.70±0.07, while with TLG defined as the
product of SUVrc and MV, the AUC was 0.75±0.06. Neither
of these two values was significantly different from the AUC
obtained with the original TLG (0.74±0.06), suggesting that
these different TLG definitions do not help in distinguishing
responding from nonresponding tumours.
As we observed that the MV change provided some
useful information for assessing tumour response, we also
studied the tumour classification in a 2-D plan with change
in SUV corrected for PVE on the x-axis and change in MV
on the y-axis (results not shown). The tumour classification
was not improved by this 2-D analysis and including MV
information through a single index not corrected for PVE
appeared more robust than considering independently the
change in MV and in SUV corrected for PVE.
Limitations of the study
In this investigation, we used the tumour classification
obtained using the RECIST 1.0 criteria calculated 6 to
8 weeks after treatment initiation as a reference to determine
the relevance of the tumour classification based on an early
PET scan performed 2 weeks after treatment initiation. The
indices calculated from the early PET scans and yielding the
highest AUC therefore corresponded to the indices that best
predicted the response seen 4 to 6 weeks later using the CT
scan. RECIST is a surrogate end-point. Even if PET would
have been of better predictive value than a late RECIST
measurement for predicting outcome, any difference be-
tween metabolic information and the reference used here
would be interpreted as a false-positive or false-negative
result, and hence yield an AUC less than 1. Additional
investigations regarding the role of PVE correction in tu-
mour response assessment by considering progression-free
survival or overall survival as end-points are still needed.
Also, we did not validate the accuracy of the measurements
performed by the different indices in the early PET scans,
but only their ability to predict the anatomical response later
seen on the CT scan.
About 75 % of the 101 lesions in our sample were classi-
fied as nonresponding lesions by RECIST 1.0. This implies
that our results probably overestimated the specificity, and
hence the ROC curves tended to be biased towards the line
of no discrimination. Yet the lack of balance between the
number of responding and nonresponding lesions was taken
into account during the statistical analysis, and did not bias the
comparative assessment of the different indices.
This study focused on the early metabolic tumour response.
The role of PVE correction when characterizing the tumour
response at later stages of therapy, i.e. when the shrinkage in
tumour volume is large in responding tumours, still needs to
be determined.
Last, our results were obtained for a particular lesion type in
patients suffering from mCRC. Whether our results hold for
different types of lesions remains to be demonstrated. In addi-
tion, it would be worth determining how other types of infor-
mation drawn from the lesions, such as textural information
[37] that has been recently demonstrated to better predict
tumour response than SUV in oesophageal cancer lesions
[38], would compare with the indices included in our study
in the context of early assessment of response to therapy.
Conclusion
In 40 patients with mCRC with 101 lesions (28 % less than
5mL), we found that SUVmax, SUVmean, SUVpeak, SUV70 and
TLG calculated in early PET scans (2 weeks after starting
therapy) and comparedwith the corresponding baseline values
all accurately predicted the late response (at 6 to 8 weeks on
therapy) determined using the RECIST criteria in CT scans.
Characterizing the change in lesion metabolic activity using
an SUV corrected for PVE did not improve the discrimination
of responding and non-responding lesions, possibly due to the
fact that PVE correction removes most information pertaining
to the MV. Considering the change in MVonly between the
baseline and early PET scans yielded a poor prediction of the
response to therapy later identified on the CT scan.
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